Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-05-14
Watson David O. Files Apellis Pharmaceuticals (APLS) Form 4 - May 14, 2026
Watson David O. traded 625.4K APLS shares in this Form 4 filing, reported to the SEC on 2026-05-14.
- Insider
- Watson David O.
- Issuer
- Apellis Pharmaceuticals Inc. APLS · NASDAQ
- Filed
- Period
- 2026-05-14
- Accession
- 0001193125-26-224583
- Source
- Official filing on sec.gov ↗
Transactions (16)
| Insider | Date | Type | Shares | Price | Value | Own |
|---|---|---|---|---|---|---|
| Watson David O. | 2026-05-14 | Sell | 144.5K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 10.0K | - | $0.00 | Indirect |
| Watson David O. | 2026-05-14 | Sell | 50.1K | - | $0.00 | Indirect |
| Watson David O. | 2026-05-14 | Buy | 41.2K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 41.2K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Buy | 28.5K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 28.5K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Buy | 28.0K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 28.0K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Buy | 56.0K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 56.0K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 32.1K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 56.0K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 11.9K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 6.0K | - | $0.00 | Direct |
| Watson David O. | 2026-05-14 | Sell | 7.4K | - | $0.00 | Direct |
| Net change | −317.9K | $0.00 | ||||
About Apellis Pharmaceuticals Inc.
Apellis Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing novel therapeutic compounds to address complement-mediated diseases. The primary focus of Apellis is to pioneer medicines leveraging targeted inhibition of the complement system, a key component of the immune system that plays a crucial role in a variety of diseases. The company's flagship product, targeting diseases such as geographic atrophy and paroxysmal nocturnal hemoglobinuria (PNH), highlights its commitment to addressing unmet medical needs with innovative treatments. Apellis Pharmaceuticals operates in the highly competitive pharmaceutical and biotechnology industry, collaborating with healthcare providers and research institutions to advance clinical treatment options. Headquartered in Waltham, Massachusetts, its contributions to medical science are significant, paving the way for advancements in immunology and therapy development. As a publicly traded entity, Apellis influences the healthcare sector by enhancing treatment paradigms and offering new hope for patients with chronic and debilitating conditions.
Track APLS insider activity
Get alerted when Apellis Pharmaceuticals Inc. executives buy or sell their shares.